IKT · Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics reported a Q1 2026 net loss of $16.4 million, or $0.10 per share, widening from $13.7 million, or $0.15 per share, in the prior-year quarter, primarily driven by higher selling, general, and administrative expenses of $7.4 million versus $5.2 million, while R&D expenses remained stable at $10.8 million compared to $10.5 million (which included a one-time $7.4 million IPR&D charge from the CorHepta acquisition). CEO Mark Iwicki highlighted excitement over enrolling the first patient in the registrational Phase 3 IMPROVE-PAH study for IKT-001 in PAH, with approvals secured in 16 countries including the US, Canada, New Zealand, Argentina, and 12 EU countries via the new EMA FAST-EU initiative. The adaptive two-part study features a 12-week dose titration, Part A targeting PVR change in 140 patients, and Part B focusing on 6MWD in 346 patients with potential sample size adjustment. Cash position stood strong at $170.4 million as of March 31, supporting ongoing global site activations. The company also submitted an Orphan Drug Designation application for IKT-001 recognizing PAH's impact on 50,000 Americans, and plans two ATS conference presentations on IKT-001 data. Balance sheet shows cash equivalents at $49.6 million and marketable securities at $120.8 million, with operating cash burn of $12.1 million; financing activities added $2.9 million from stock issuance.